share_log

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K：重大事件
美股sec公告 ·  03/26 17:31
Moomoo AI 已提取核心訊息
On March 25, 2024, Mangoceuticals, Inc. held a Special Meeting where stockholders approved significant proposals, including a reverse stock split and an amendment to the company's Equity Incentive Plan. The reverse stock split, which was approved by approximately 91% of votes, allows the Board of Directors to consolidate shares at a ratio between one-for-two and one-for-fifty, at their discretion, anytime before March 25, 2025. Additionally, the First Amendment to the Mangoceuticals, Inc. 2022 Equity Incentive Plan was approved, which includes an 'evergreen' provision allowing for an automatic increase in the number of shares available for awards annually for nine years, starting April 1, 2024. The plan provides various equity awards to employees, officers, directors, and consultants, with a cap of 26,000,000 shares for issuance or grants under the plan in total, and the same amount for Incentive Stock Options. The meeting saw a quorum with 74.1% of the voting shares present, and all proposals described in the Proxy Statement filed on March 1, 2024, were approved.
On March 25, 2024, Mangoceuticals, Inc. held a Special Meeting where stockholders approved significant proposals, including a reverse stock split and an amendment to the company's Equity Incentive Plan. The reverse stock split, which was approved by approximately 91% of votes, allows the Board of Directors to consolidate shares at a ratio between one-for-two and one-for-fifty, at their discretion, anytime before March 25, 2025. Additionally, the First Amendment to the Mangoceuticals, Inc. 2022 Equity Incentive Plan was approved, which includes an 'evergreen' provision allowing for an automatic increase in the number of shares available for awards annually for nine years, starting April 1, 2024. The plan provides various equity awards to employees, officers, directors, and consultants, with a cap of 26,000,000 shares for issuance or grants under the plan in total, and the same amount for Incentive Stock Options. The meeting saw a quorum with 74.1% of the voting shares present, and all proposals described in the Proxy Statement filed on March 1, 2024, were approved.
2024年3月25日，Mangoceuticals, Inc.舉行了一次特別會議，股東們批准了重要提案，包括反向股票拆分和公司股權激勵計劃的修正案。反向股票拆分獲得了大約 91% 的選票的批准，允許董事會在2025年3月25日之前的任何時候自行決定以一比二和一比五的比例合併股份。此外，Mangoceuticals, Inc. 2022年股權激勵計劃的第一修正案獲得批准，其中包括一項 “常青” 條款，允許自2024年4月1日起在九年內自動增加每年可供獎勵的股票數量。該計劃向員工、高級職員、董事和顧問提供各種股權獎勵，根據該計劃總髮行或贈款的上限爲26,000,000股，激勵性股票期權的上限爲相同金額。會議達到了法定人數，有74.1％的有表決權的股份出席，2024年3月1日提交的委託書中描述的所有提案均獲得批准。
2024年3月25日，Mangoceuticals, Inc.舉行了一次特別會議，股東們批准了重要提案，包括反向股票拆分和公司股權激勵計劃的修正案。反向股票拆分獲得了大約 91% 的選票的批准，允許董事會在2025年3月25日之前的任何時候自行決定以一比二和一比五的比例合併股份。此外，Mangoceuticals, Inc. 2022年股權激勵計劃的第一修正案獲得批准，其中包括一項 “常青” 條款，允許自2024年4月1日起在九年內自動增加每年可供獎勵的股票數量。該計劃向員工、高級職員、董事和顧問提供各種股權獎勵，根據該計劃總髮行或贈款的上限爲26,000,000股，激勵性股票期權的上限爲相同金額。會議達到了法定人數，有74.1％的有表決權的股份出席，2024年3月1日提交的委託書中描述的所有提案均獲得批准。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息